Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2005-01-11
2005-01-11
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S071000, C558S146000
Reexamination Certificate
active
06841545
ABSTRACT:
The present invention relates to a sterile, stable dosage forms suitable for reconstitution and parenteral administration to a patient, said dosage form comprising an amorphous aminoalkyl dihydrogen phosphorothioate, and of amifostine in particular. The invention further relates to a method of preparing such a dosage form, which typically exhibits enhanced thermal stability as compared to existing vacuum dried amorphous amifostine.
REFERENCES:
patent: 3892824 (1975-07-01), Piper et al.
patent: 4424216 (1984-01-01), Cerami et al.
patent: 5424471 (1995-06-01), Kennedy et al.
patent: 5488042 (1996-01-01), Grdina
patent: 5591731 (1997-01-01), Kennedy et al.
patent: 54-46722 (1979-04-01), None
patent: WO 8905637 (1989-06-01), None
patent: WO 9507700 (1995-03-01), None
patent: WO 9711666 (1997-04-01), None
patent: 98-34622 (1998-08-01), None
Treskes et al. “Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR 2721 in the mouse”Cancer Res.52:2257-2260 (1992).
Treskes, M. et al.,Anticancer Drug Res.6(4):303 (1991).
Geary et al., “Characterization of ethiofos absorption in the rat small intestine”Biopharmaceuticals&Drug Disposition12:261-274 (1991).
Geary et al., “Characterization of ethiofos absorption in the rat small intestine”Biopharmaceuticals&Drug Disposition12:275-284 (1991).
Zadeii et al., “Stability of Ethiofos (NSC-29691) in aqueous solution and solid phase formulation”Pharm. Res.(NY) 8(10 Suppl.):S174 (1991).
Jahansouz, H. et al. “Stability of ethiofos (NSC-29691) in aqueous solution and solid phase formulation”Pharm. Res.(NY) 7(9):S195 (1990).
Walden, T.L. Jr., et al., “Thermospray liquid chromotography mass spectrometry of thiol radioprotective agents: characteristic spectra”Pharmac. Ther.39:219-221 (1988).
Karle and Karle, Acta. Chryst. C44: 135-138 (1987).
Starke and Farber, “Ferric iron and superoxide ions are required for the killing of cultured hepatocytes by hydrogen peroxide”J. Biol. Chem.260(18):10099-10104 (1985).
Eichler et al., “Radiation inactivation analysis of enzymes”J. Biol. Chem.262(20):9433-9436 (1984).
Blackburn, P., et al., “Thio-disulfide interchange between cystine and N-2-mercaptoethyl-1,3-diaminopropane as a potential treatment for cystinuria”Analytical Biochem.136:31-38 (1984).
Remington's Pharmaceutical Sciences, 18thed., 1990, pp. 1470-1480, 1545-1569.
Bohuslavizki et al., “Protection of salivary glands by amifostine in patients treated with high dose radioiodine”, Eu. Jour. Cancer 33: S17 (1997).
Fitchner et al., “Effects of amifostine on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas”, Anti-cancer Drugs 8(2): 174-181 (1997).
Foster-Nora et al., “Amifostine for protection from antineoplastic drug toxicity”, Am. Jour. Health-system Pharm. 54(7): 787-800 (1997).
Kemp et al., “Amifostine pretreatment for protection against cyclophosphatide-induced and cisplastin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer”, Jour. Clin. Oncology 14(7): 2101-2112 (1996).
Lewis, “A review of the use of chemoprotectants in cancer chemotherapy”, Drug Safety: An International Journal of Medical Toxicology and Drug Experience 11(3): 153-162 (1994).
Spencer et al., “Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector”, Drugs 50(6): 1001-1031 (1995).
Stogniew Martin
Zadei Javad M.
MedImmune Oncology Inc.
Raymond Richard L.
Tucker Zachary C.
LandOfFree
Stable amorphous amifostine compositions and methods for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable amorphous amifostine compositions and methods for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable amorphous amifostine compositions and methods for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3430909